382 related articles for article (PubMed ID: 29470609)
41. Novel topical and systemic therapies in atopic dermatitis.
Suga H; Sato S
Immunol Med; 2019 Jun; 42(2):84-93. PubMed ID: 31318324
[TBL] [Abstract][Full Text] [Related]
42. Itch in Atopic Dermatitis Management.
Kamata Y; Tominaga M; Takamori K
Curr Probl Dermatol; 2016; 50():86-93. PubMed ID: 27578076
[TBL] [Abstract][Full Text] [Related]
43. What's new in atopic eczema? An analysis of systematic reviews published in 2018. Part 2: systemic therapies.
Olabi B; Worboys S; Garland T; Grindlay DJC; Rogers NK; Harman KE
Clin Exp Dermatol; 2020 Dec; 45(8):980-985. PubMed ID: 32568435
[TBL] [Abstract][Full Text] [Related]
44. Interleukin antagonists for atopic dermatitis: a new era of therapy.
Tsiogka A; Paschou E; Koumaki D; Vakirlis E; Gregoriou S
Expert Opin Investig Drugs; 2024 Jun; 33(6):549-559. PubMed ID: 38656240
[TBL] [Abstract][Full Text] [Related]
45. Use patterns of systemic immunomodulators in the United States before and after dupilumab approval in adults with atopic dermatitis.
Anand P; Schneeweiss S; Mostaghimi A; Schneeweiss MC
Pharmacoepidemiol Drug Saf; 2023 May; 32(5):567-576. PubMed ID: 36527432
[TBL] [Abstract][Full Text] [Related]
46. Dupilumab in the treatment of severe atopic dermatitis refractory to systemic immunosuppression: case report.
Giavina-Bianchi MH; Giavina-Bianchi P; Rizzo LV
Einstein (Sao Paulo); 2019 Jul; 17(4):eRC4599. PubMed ID: 31291386
[TBL] [Abstract][Full Text] [Related]
47. The evolving atopic dermatitis management landscape.
Sahni VN; Balogh EA; Strowd LC; Feldman SR
Expert Opin Pharmacother; 2022 Mar; 23(4):517-526. PubMed ID: 34758685
[TBL] [Abstract][Full Text] [Related]
48. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.
Serra-Baldrich E; Santamaría-Babí LF; Francisco Silvestre J
Actas Dermosifiliogr; 2022; 113(7):674-684. PubMed ID: 35842249
[TBL] [Abstract][Full Text] [Related]
49. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
[TBL] [Abstract][Full Text] [Related]
50. Systemic Agents for Severe Atopic Dermatitis in Children.
Notaro ER; Sidbury R
Paediatr Drugs; 2015 Dec; 17(6):449-57. PubMed ID: 26547214
[TBL] [Abstract][Full Text] [Related]
51. Emerging treatments for atopic dermatitis.
Katoh N
J Dermatol; 2021 Feb; 48(2):152-157. PubMed ID: 32677122
[TBL] [Abstract][Full Text] [Related]
52. The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis.
Silverberg JI; Kantor R
Dermatol Clin; 2017 Jul; 35(3):327-334. PubMed ID: 28577802
[TBL] [Abstract][Full Text] [Related]
53. A case of complete recovery in a hypereosinophilic dermatitis patient with dupilumab.
Jiang X; Ye J; Wu X; Zhu J; Chen S; Cheng H
Inflamm Res; 2023 Apr; 72(4):875-878. PubMed ID: 36912915
[TBL] [Abstract][Full Text] [Related]
54. Dupilumab: First Global Approval.
Shirley M
Drugs; 2017 Jul; 77(10):1115-1121. PubMed ID: 28547386
[TBL] [Abstract][Full Text] [Related]
55. Dupilumab for the treatment of atopic dermatitis: A clinical trial review.
McGregor S; Farhangian ME; Feldman SR
Expert Opin Biol Ther; 2015; 15(11):1657-60. PubMed ID: 26428945
[TBL] [Abstract][Full Text] [Related]
56. Towards personalized treatment in atopic dermatitis.
van der Schaft J; Thijs JL; Garritsen FM; Balak D; de Bruin-Weller MS
Expert Opin Biol Ther; 2019 May; 19(5):469-476. PubMed ID: 30768375
[TBL] [Abstract][Full Text] [Related]
57. Longitudinal utilization of systemic immunomodulators before and after dupilumab approval in children with atopic dermatitis.
Anand P; Schneeweiss S; Mostaghimi A; Schneeweiss MC
Pediatr Dermatol; 2023 Jan; 40(1):132-134. PubMed ID: 36403606
[TBL] [Abstract][Full Text] [Related]
58. Therapeutic pipeline for atopic dermatitis: End of the drought?
Paller AS; Kabashima K; Bieber T
J Allergy Clin Immunol; 2017 Sep; 140(3):633-643. PubMed ID: 28887947
[TBL] [Abstract][Full Text] [Related]
59. Current novel approaches in systemic therapy of atopic dermatitis: specific inhibition of cutaneous Th2 polarized inflammation and itch.
Werfel T; Biedermann T
Curr Opin Allergy Clin Immunol; 2015 Oct; 15(5):446-52. PubMed ID: 26308331
[TBL] [Abstract][Full Text] [Related]
60. Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature.
Blakely K; Gooderham M; Papp K
Skin Therapy Lett; 2016 Mar; 21(2):1-5. PubMed ID: 27223113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
